BeiGene (ONC) reported Q1 adjusted earnings Wednesday of $1.22 per diluted American depositary share, swinging from an adjusted loss of $1.40 a year earlier.
Comparable analyst estimates were not readily available.
Revenue for the quarter ended March 31 was $1.12 billion, up from $751.7 million a year earlier.
Analysts surveyed by FactSet expected $1.13 billion.
For 2025, the biotech company continues to expect revenue of $4.9 billion to $5.3 billion.
Analysts polled by FactSet expect $5.07 billion.
Shares of the company were down more than 5% in recent premarket activity.
Price: 229.00, Change: -12.75, Percent Change: -5.27
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。